PTC Therapeutics, Inc. Noncash or Part Noncash Acquisition, Intangible Assets Acquired
PTC Therapeutics, Inc. (PTCT) reported Noncash or Part Noncash Acquisition, Intangible Assets Acquired of $4.57 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1 · last filed 2026-07-30
- PTC Therapeutics, Inc. noncash or part noncash acquisition, intangible assets acquired for the quarter ending 2026-06-30 was -$726.00K, a 826.00% decline year-over-year.
- PTC Therapeutics, Inc. noncash or part noncash acquisition, intangible assets acquired for the quarter ending 2026-03-31 was $5.29M, a 142.20% increase year-over-year.
- PTC Therapeutics, Inc. noncash or part noncash acquisition, intangible assets acquired for the quarter ending 2025-12-31 was -$854.00K.
- PTC Therapeutics, Inc. noncash or part noncash acquisition, intangible assets acquired for the quarter ending 2025-09-30 was -$64.00K.
- PTC Therapeutics, Inc. noncash or part noncash acquisition, intangible assets acquired for fiscal 2025 was $1.37M, a 225.48% increase from fiscal 2024.
- PTC Therapeutics, Inc. noncash or part noncash acquisition, intangible assets acquired for fiscal 2024 was $420.00K, a 99.23% decline from fiscal 2023.
- PTC Therapeutics, Inc. noncash or part noncash acquisition, intangible assets acquired for fiscal 2023 was $54.62M, a 64.32% increase from fiscal 2022.
- PTC Therapeutics, Inc. noncash or part noncash acquisition, intangible assets acquired for fiscal 2022 was $33.24M, a 49.09% increase from fiscal 2021.
| Period end | Noncash or Part Noncash Acquisition, Intangible Assets Acquired 3 month | Noncash or Part Noncash Acquisition, Intangible Assets Acquired 6 month | Noncash or Part Noncash Acquisition, Intangible Assets Acquired 9 month | Noncash or Part Noncash Acquisition, Intangible Assets Acquired 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$726.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $4.57M 10-Q · filed 2026-07-30 | $3.71M derived: sum of 3 quarters · filed 2026-07-30 | $3.65M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $5.29M 10-Q · filed 2026-05-07 | $4.44M derived: sum of 2 quarters · filed 2026-05-07 | $4.37M derived: sum of 3 quarters · filed 2026-05-07 | $4.47M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | -$854.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$918.00K derived: sum of 2 quarters · filed 2026-02-19 | -$818.00K derived: sum of 3 quarters · filed 2026-07-30 | $1.37M 10-K · filed 2026-02-19 |
| 2025-09-30 | -$64.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $36.00K derived: sum of 2 quarters · filed 2026-07-30 | $2.22M 10-Q · filed 2025-11-04 | $295.00K derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $100.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $2.29M 10-Q · filed 2026-07-30 | $359.00K derived: sum of 3 quarters · filed 2026-07-30 | -$400.00K derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $2.19M 10-Q · filed 2026-05-07 | $259.00K derived: sum of 2 quarters · filed 2026-05-07 | -$500.00K derived: sum of 3 quarters · filed 2026-05-07 | $309.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$1.93M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$2.69M derived: sum of 2 quarters · filed 2026-02-19 | -$1.88M derived: sum of 3 quarters · filed 2026-02-19 | $420.00K 10-K · filed 2026-02-19 |
| 2024-09-30 | -$759.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $50.00K derived: sum of 2 quarters · filed 2025-11-04 | $2.35M 10-Q · filed 2025-11-04 | $12.00M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | $809.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $3.10M 10-Q · filed 2025-08-07 | $12.76M derived: sum of 3 quarters · filed 2026-02-19 | $20.84M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | $2.30M 10-Q · filed 2025-05-06 | $11.95M derived: sum of 2 quarters · filed 2026-02-19 | $20.04M derived: sum of 3 quarters · filed 2026-02-19 | $37.51M derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | $9.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $17.74M derived: sum of 2 quarters · filed 2026-02-19 | $35.21M derived: sum of 3 quarters · filed 2026-02-19 | $54.62M 10-K · filed 2026-02-19 |
| 2023-09-30 | $8.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $25.56M derived: sum of 2 quarters · filed 2024-11-07 | $44.96M 10-Q · filed 2024-11-07 | $50.37M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $17.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $36.88M 10-Q · filed 2024-08-08 | $42.29M derived: sum of 3 quarters · filed 2025-02-27 | $43.43M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $19.41M 10-Q · filed 2024-04-25 | $24.82M derived: sum of 2 quarters · filed 2025-02-27 | $25.96M derived: sum of 3 quarters · filed 2025-02-27 | $40.06M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $5.41M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $6.55M derived: sum of 2 quarters · filed 2025-02-27 | $20.65M derived: sum of 3 quarters · filed 2025-02-27 | $33.24M 10-K · filed 2025-02-27 |
| 2022-09-30 | $1.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-26 | $15.24M derived: sum of 2 quarters · filed 2023-10-26 | $27.83M 10-Q · filed 2023-10-26 | $30.97M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $14.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $26.69M 10-Q · filed 2023-08-03 | $29.83M derived: sum of 3 quarters · filed 2024-02-29 | $30.61M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $12.59M 10-Q · filed 2023-04-27 | $15.73M derived: sum of 2 quarters · filed 2024-02-29 | $16.51M derived: sum of 3 quarters · filed 2024-02-29 | $26.01M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $3.14M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $3.92M derived: sum of 2 quarters · filed 2024-02-29 | $13.42M derived: sum of 3 quarters · filed 2024-02-29 | $22.29M 10-K · filed 2024-02-29 |
| 2021-09-30 | $785.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-27 | $10.28M derived: sum of 2 quarters · filed 2022-10-27 | $19.15M 10-Q · filed 2022-10-27 | $19.56M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-06-30 | $9.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $18.37M 10-Q · filed 2022-08-04 | $18.77M derived: sum of 3 quarters · filed 2023-02-21 | $20.37M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-03-31 | $8.87M 10-Q · filed 2022-05-03 | $9.28M derived: sum of 2 quarters · filed 2023-02-21 | $10.88M derived: sum of 3 quarters · filed 2023-02-21 | $20.29M derived: sum of 4 quarters · filed 2023-02-21 |
| 2020-12-31 | $405.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $2.00M derived: sum of 2 quarters · filed 2023-02-21 | $11.42M derived: sum of 3 quarters · filed 2023-02-21 | $14.19M 10-K · filed 2023-02-21 |
| 2020-09-30 | $1.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-28 | $11.01M derived: sum of 2 quarters · filed 2021-10-28 | $13.79M 10-Q · filed 2021-10-28 | $17.79M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-06-30 | $9.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | $12.19M 10-Q · filed 2021-07-29 | $16.19M derived: sum of 3 quarters · filed 2022-02-22 | $15.35M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-03-31 | $2.77M 10-Q · filed 2021-05-04 | $6.78M derived: sum of 2 quarters · filed 2022-02-22 | $5.94M derived: sum of 3 quarters · filed 2022-02-22 | $14.21M derived: sum of 4 quarters · filed 2022-02-22 |
| 2019-12-31 | $4.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22 | $3.17M derived: sum of 2 quarters · filed 2022-02-22 | $11.43M derived: sum of 3 quarters · filed 2022-02-22 | $11.43M 10-K · filed 2022-02-22 |
| 2019-09-30 | -$837.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | $7.43M derived: sum of 2 quarters · filed 2020-10-29 | $7.43M 10-Q · filed 2020-10-29 | $8.88M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $8.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $8.27M 10-Q · filed 2020-08-05 | $9.72M derived: sum of 3 quarters · filed 2021-02-25 | $10.35M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $0.00 10-Q · filed 2020-04-30 | $1.45M derived: sum of 2 quarters · filed 2021-02-25 | $2.08M derived: sum of 3 quarters · filed 2021-02-25 | |
| 2018-12-31 | $1.45M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $2.08M derived: sum of 2 quarters · filed 2021-02-25 | $5.98M 10-K · filed 2021-02-25 | |
| 2018-09-30 | $627.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30 | $4.53M 10-Q · filed 2019-10-30 | ||
| 2018-06-30 | $3.90M 10-Q · filed 2019-08-06 | |||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $0.00 10-K · filed 2020-03-02 | ||
| 2017-09-30 | $0.00 10-Q · filed 2018-11-05 | |||
| 2016-12-31 | $0.00 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |